Cite
1074TiP A phase I/II, open label, first-in-human, dose escalation and expansion study of SAR445877 administered as monotherapy in adults with advanced solid tumors.
MLA
Gutierrez, M., et al. “1074TiP A Phase I/II, Open Label, First-in-Human, Dose Escalation and Expansion Study of SAR445877 Administered as Monotherapy in Adults with Advanced Solid Tumors.” Annals of Oncology, vol. 34, Oct. 2023, pp. S646–47. EBSCOhost, https://doi.org/10.1016/j.annonc.2023.09.2213.
APA
Gutierrez, M., Garralda, E., Calvo, E., van Dongen, M., Eskens, F. A., Finlay, M., Menas, F.-Z., Zhu, C., Wu, M., Guillemin-Paveau, H., Abbadessa, G., Perez, R., Yildirim, O., & Naing, A. (2023). 1074TiP A phase I/II, open label, first-in-human, dose escalation and expansion study of SAR445877 administered as monotherapy in adults with advanced solid tumors. Annals of Oncology, 34, S646–S647. https://doi.org/10.1016/j.annonc.2023.09.2213
Chicago
Gutierrez, M., E. Garralda, E. Calvo, M. van Dongen, F.A. Eskens, M. Finlay, F-Z. Menas, et al. 2023. “1074TiP A Phase I/II, Open Label, First-in-Human, Dose Escalation and Expansion Study of SAR445877 Administered as Monotherapy in Adults with Advanced Solid Tumors.” Annals of Oncology 34 (October): S646–47. doi:10.1016/j.annonc.2023.09.2213.